VS 105

Drug Profile

VS 105

Alternative Names: VS-105

Latest Information Update: 05 Aug 2016

Price : $50

At a glance

  • Originator Vidasym
  • Class Osteoporosis therapies; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Osteoporosis; Renal failure

Highest Development Phases

  • Preclinical Osteoporosis; Renal failure

Most Recent Events

  • 05 Aug 2016 VS 105 is still in preclinical development for Renal failure and Osteoporosis in USA
  • 05 Aug 2016 VS 105 is available for licensing as of 05 Aug 2016. http://vidasym.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top